Navigation Links
Ambrx to Present Phase I/II Clinical Data for Optimized, Long Acting Human Growth Hormone Analogue
Date:11/5/2008

SAN DIEGO, Nov. 5 /PRNewswire/ -- Ambrx Inc. today announced the scheduled presentation of data from a Phase I/II clinical trial of ARX201, the company's long-acting human growth hormone (hGH) analogue developed in collaboration with Merck Serono, at the International Congress of Endocrinology meeting in Rio de Janeiro. Andrew R. Hoffman, M.D., Professor of Medicine and Vice President of Academic Affairs at Stanford University, will present the clinical results as part of an oral presentation at 9:30 AM local time (GMT -3 / 7:30 AM EST) on November 12, 2008.

The Phase I/II dose-finding study in adult patients with growth hormone deficiency investigated the safety, tolerability, pharmacokinetic and pharmacodynamic profile of ARX201 following single-dose escalation and repeated dosing. The study analyzed 22 individuals with adult growth hormone deficiency (AGHD). The patients had not received hGH replacement therapy in the six months prior to the study.

ARX201 was administered once weekly by subcutaneous injection. Dosing was titrated based on IGF-I response and/or safety findings. Patients were treated for up to 26 weeks. Clinical measures of body composition were taken at the end of the study period.

About ARX201

ARX201 is a long-acting recombinant human growth hormone drug candidate currently developed by Ambrx and Merck Serono for the treatment of growth hormone deficiencies. ARX201 was generated through a lead optimization process using Ambrx's ReCODE(TM) technology, which effectively enables protein medicinal chemistry. Through this approach, Ambrx was able to generate site specific mono-pegylated hGH molecules that were optimized for potency and time of action. Ambrx believes that ARX201 may have improved pharmacological performance over existing growth hormone products, including the potential for less frequent dosing.

In pre-clinical studies, ARX201 met or exceeded key end points in assays that are believed to be pred
'/>"/>

SOURCE Ambrx Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Ambrx Appoints Douglas Axelrod Senior Vice President for Clinical Research and Development
2. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
3. Avicena Group to Present at Noble Financial Conference
4. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
5. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
6. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
7. CEL-SCI to Present at the Noble Financial Conference
8. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
9. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
10. Strategic Diagnostics Updates Roth Conference Presentation Time
11. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...STON, Nov. 24 IES (Nasda...cal and communications systems and services for th...announced today that its commercial business group... JV to install the electrical systems for the Leve... the U.S. Army Medical Research Institute of Infec...
(Date:11/24/2009)... and BLENHEIM, Ontario, Nov. 24 /PRNewswire-FirstC... is acquiring the assets of Hyland Seeds, a divisi...addition of Hyland Seeds will further expand Dow A... anticipates the introduction of SmartStax(TM) i... Trait Technology in corn in 2012. The transaction...
(Date:11/24/2009)... , REYKJAVIK, Iceland, November 24 /PRNewsw...CGN ) today announced the approval of all of its,"...r the District of Delaware,(the "Bankruptcy Court"...,relief under Chapter 11 of the United States Bank...The orders issued by the Bankruptcy Court allow th...
(Date:11/24/2009)....24/PRNewswire/--BlueMarbleEnergyCorp.announcedtod...rity(OPDA)wererecentlyawarded$2millionbyWashington...naprivate/publicpartnershiptoconstructthestate,sfi...WA. ,, "Thisinvestmentwillsignificantlyspeedthe...toLincolnCounty,"saidBlueMarbleEnergyCEOKellyOgilv...
Breaking Biology Technology:Integrated Electrical Services Awarded Contract to Provide Electrical Systems for U.S. Army Medical Research Institute of Infectious Diseases 2Dow AgroSciences Canada Announces Agreement to Acquire Hyland Seeds 2Dow AgroSciences Canada Announces Agreement to Acquire Hyland Seeds 3deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 2deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 3Blue Marble Energy, OPDA Awarded $2M by WA's Community Economic Revitalization Board 2
...GO, May 13 ADVENTRX Pharmaceuticals,Inc. (Amex: ...X,s Chief,Executive Officer and President, is sche...l Global Healthcare Conference. Mr. Levine is sche...p.m. Central European Summer Time,in the Atlantiqu...ference,takes place May 19 - 20, 2008 at the Le Me...
...GO, May 12 Anadys Pharmaceuticals,Inc. (Nasdaq: ... Rodman &,Renshaw 5th Annual Global Healthcare Con... (4:00 a.m. EDT/1:00 a.m. PDT) at Le Meridien Beac...d, Ph.D., President and Chief,Executive Officer of...,update on its two development-stage product candi...
...GE, Mass., May 12 Idenix,Pharmaceuticals, Inc. (N...ent,will present a corporate overview at the Rodma...e on Tuesday, May 20, 2008 at 12:00 p.m. CEST at L...o., The live and archived webcast of the company ...ents" in the Idenix Investor Center at, http://www...
Other Biology Technology:Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences 2
(Date:11/23/2009)...earch presents strong evidence that the "synergist...traffic-related pollution and indoor endotoxin cau...other exposure alone. , Environmental health s...lege of Medicine have shown that children exposed ...nd indoor endotoxin during early life are six time...
(Date:11/23/2009)...the Wildlife Conservation Society says that wester...Republic of Congopart of the "mother lode" of more...oming increasingly threatened by growing humans ac...tection of the swamp forests adjacent to the south...nt surveys confirmed that high densities of the gr...
(Date:11/23/2009)...e only swine vaccine available for the H1N1 virus ...ith the virus. The vaccination marks the first tim...with the pandemic flu., Iowa State University,s ...d the vaccine this summer and has been shipping pr...and Illinois for several weeks., The latest vacc...
Breaking Biology News(10 mins):Exposure to both traffic, indoor pollutants puts some kids at higher risk for asthma later 2A year after discovery, Congo's 'mother lode' of gorillas remains vulnerable 2Iowa State researcher produces, ships only H1N1 vaccine available for swine 2OmniComm Systems Acquires EDC Assets of Leading Phase I Clinical Software Vendor Logos Technologies Ltd 13341 1OmniComm Systems Acquires EDC Assets of Leading Phase I Clinical Software Vendor Logos Technologies Ltd 13341 2OmniComm Systems Acquires EDC Assets of Leading Phase I Clinical Software Vendor Logos Technologies Ltd 13341 3High cholesterol in midlife raises risk of late life dementia Kaiser Permanente study finds 53591 1High cholesterol in midlife raises risk of late life dementia Kaiser Permanente study finds 53591 2High cholesterol in midlife raises risk of late life dementia Kaiser Permanente study finds 53591 3Chicagoland Motorcycle F A S T Ride to Fight Fetal Alcohol Spectrum Disorder 3A 53589 1Chicagoland Motorcycle F A S T Ride to Fight Fetal Alcohol Spectrum Disorder 3A 53589 2
...out nanotechnology and other complex but emerging ... and cautious" about the new technologies, prospec...archers at North Carolina State University. , A n...iversity on public attitudes towards nanotechnolog...nologies shows that educating people about the new...
...rs have determined a novel mechanism through which...their findings suggest that targeted therapies may...008, issue of Cancer Research , researchers at Ha...y experiments that the anti-rejection, immunosuppr...scular endothelial growth factor (VEGF), which sig...
...chers at Georgetown University Medical Center have... cancer cells, turns on genes that can push stem c... cells. These cells can then build blood vessels t...rther tumor growth. , They say their findings, pu... is a proof of principle of the new and controver...
Other Biology News:Study shows increased education on nanotech, human enhancement increases public concerns 2Researchers discover link between organ transplantation and increased cancer risk 2Vitamin A pushes breast cancer to form blood vessel cells 2Vitamin A pushes breast cancer to form blood vessel cells 3
...xcellent choice for supporting hydrocarbon process...nel GC, this one-channel workhorse can double samp...one. You get all the capability and reliability yo...at has the same proven performance of Agilents fla...
...nfusion kits reduce the time and expense of prepar...equipment to reduce the risk of infection. Each ki...luding swivel, tubing, tether and connectors. Tubi...u specify, preassembled in Instech's clean room, i...
7890A GC from Agilent Technologies
... for critical, but time-consuming optimization exp...siRNA transfection protocols resulting in less opt...an be used to efficiently transfect adherent cells...xicity. From start to finish, successful gene sile...
Biology Products: